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Spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal-dominant neurodegenerative disorders involving the cerebellum
and 23 different genes. Wemapped SCA38 to a 56Mb region on chromosome 6p in a SCA-affected Italian family by whole-genome link-
age analysis. Targeted resequencing identified a single missense mutation (c.689G>T [p.Gly230Val]) in ELOVL5. Mutation screening of
456 independent SCA-affected individuals identified the same mutation in two further unrelated Italian families. Haplotyping showed
that at least two of the three families shared a common ancestor. One further missense variant (c.214C>G [p.Leu72Val]) was found in a
French family. Both missense changes affect conserved amino acids, are predicted to be damaging by multiple bioinformatics tools, and
were not identified in ethnicallymatched controls or within variant databases. ELOVL5 encodes an elongase involved in the synthesis of
polyunsaturated fatty acids of the u3 and u6 series. Arachidonic acid and docosahexaenoic acid, two final products of the enzyme, were
reduced in the serum of affected individuals. Immunohistochemistry on control mice and human brain demonstrated high levels in
Purkinje cells. In transfection experiments, subcellular localization of altered ELOVL5 showed a perinuclear distribution with a signal
increase in the Golgi compartment, whereas the wild-type showed a widespread signal in the endoplasmic reticulum. SCA38 and
SCA34 are examples of SCAs due to mutations in elongase-encoding genes, emphasizing the importance of fatty-acid metabolism in
neurological diseases.Spinocerebellar ataxias (SCAs) are autosomal-dominant
neurological disorders with an average prevalence of 5–7
in 100,000 individuals.1,2 SCAs are phenotypically charac-
terized by gait ataxia and incoordination of eye move-
ments, speech, and hand movements and are usually
associated with cerebellar atrophy.3–6 Their genetic bases
are highly heterogeneous and only partially known.
More than 30 SCAs have been mapped, and 23 genes
have been identified, but in most countries 40%–50% of
families lack a genetic diagnosis.3,7 On the basis of the
type of mutation, three main categories of SCAs can be
identified: (1) disorders of CAG-coding polyglutamine
repeat expansions, which are the most prevalent forms
and include SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17
(MIM 164400, 183090, 109150, 183086, 164500, and
607136, respectively); (2) noncoding repeat expansions,
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The AmerSCA10 (MIM 603513), TGGAA in SCA31 (MIM 117210),
and GGCCTG in SCA36 (MIM 614153); and (3) conven-
tional mutations in genes encoding mostly unrelated pro-
teins, except for ion channels in SCA13 (MIM 605259),
SCA19 (also known as SCA22 [MIM 607346]), and episodic
ataxia types 1 and 2 (MIM 160120 and 108500, respec-
tively). SCA8 (MIM 608768) and SCA12 (MIM 604326)
have been associated with a polyglutamine disorder or an
untranslated-repeat disorder. Pathogenetic mechanisms
that underlie neurodegeneration remain poorly under-
stood and are triggered by a toxic gain of function in
polyglutamine-expanded genes, an RNA effect in polyglut-
amine and/or noncoding repeat expansions, and/or a
likely loss of function in almost all genetic entities.8
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Figure 1. Family Trees, Haplotype Analysis, and ELOVL5 Mutation Analysis
(A) Pedigrees of SCA38-affected families. Open symbols indicate unaffected family members, and solid black symbols indicate affected
members. Lines above the symbols indicate individuals for whom DNA was available. The genotype of the ELOVL5 mutations is indi-
cated below each tested subject.
(B) Microsatellite genotypes with haplotype reconstruction of family SCA38-01-BS. Arrows indicate recombination events in healthy
subjects IV-3 and IV-4; these events define the minimal region (boxed). On the right, distances of the markers from the top of chromo-
some 6p are indicated in Mb.
(C) Electropherograms of missense mutations c.214C>G (p.Leu72Val) and c.689G>T (p.Gly230Val).
(D) The amino acid sequence alignment of a portion of the human ELOVL5 in various orthologs. The two changed amino acids are
conserved through vertebrates.regulation, protein aggregation and clearance, the ubiqui-
tin-proteasome system, and alterations of calcium homeo-
stasis. In the present study, we mapped SCA38, a form of
SCA due to mutations in ELOVL fatty acid elongase 5
(ELOVL5 [MIM 611805]).
We collected a large Italian family with seven members
affected by a pure form of cerebellar ataxia (family
SCA38-01-BS, Figure 1A). The participants or an authorized
representative provided written informed consent. The
ethics committee of the Hospital of Brescia in Italy pro-
vided ethical approval.
All clinical evaluations includeda fullmedicalhistory and
examination, estimation of the age of onset, observation of
additional neurological signs, electroneuromyographic
studies, and whenever possible, brainMRI and/or fluorode-
soxyglucose positron emission tomography (FDG-PET)
scans. Epstein-Barr-virus-transformed lymphoblastoid cell210 The American Journal of Human Genetics 95, 209–217, August 7lines were available for five affected individuals: subjects
III-5 and III-10 from family SCA38-01-BS and subjects
IV-8, IV-9, and IV-12 from family SCA38-02-CA.
Initially, CAG expansions within genes involved in SCA
were excluded. Genome-wide linkage analysis was per-
formed on seven affected individuals (II-6, III-1, III-3,
III-6, III-10, IV-1, and IV-2) and three healthy relatives
(III-4, III-11, and III-12) with the Illumina LINKAGE_12
microarray, containing 6,090 SNP markers with an average
gap of 441 kb and 0.58 cM across the genome, according to
the manufacturer’s protocol.
Three regions showed suggestive genetic linkage with
Z > 1.5 (Figure S1A, available online): on chromosome 6,
the region between rs560194 and rs2180419 (10.5–21.7
Mb) showed Zmax ¼ þ2.3 and the region between
rs159988 and rs7776325 (25.1–99.9 Mb) showed Zmax ¼
þ2.8, and on chromosome 10, the region between, 2014
rs10824792 and rs736594 (54.5–71.2 Mb) showed Zmax ¼
þ1.7. In addition, nine regions presented with uninforma-
tivemultipoint LOD scores ranging from1.9 toþ0.1; two
of them overlapped with SCA25- and SCA28-associated
loci (Figure S1A).
To confirm linkage and refine mapping, we further gen-
otyped the above affected individuals and four additional
family members (II-3, III-7, IV-3, and IV-4) for 21 microsat-
ellite markers located on chromosome 6 (UCSC Genome
Browser hg19 and Table S1). Healthy status of subjects
IV-3 and IV-4 was ascertained by neurologic examination
and a FDG-PET scan when they were 40 years of age.
A significant multipoint LOD score (Zmax ¼ þ3.08) was
found in a single region between markers D6S1610 and
chr6_AC73.9 (Figure S1B).Haplotype analysis of the recom-
binant individuals restricted this locus, which we named
SCA38 in agreement with the HUGO nomenclature, to a
56.2 Mb interval flanked by markers D6S276 (24.2 Mb)
and D6S460 (80.4 Mb) on 6p22.2–q14.1 (Figure 1B).
Using custom array comparative genomic hybridi-
zation, we did not identify any deletions or duplications
in this candidate region in the genomic DNA of
subject III-7 from family SCA38-01-BS (custom design con-
taining 3,700 probes between positions 50,854,000 and
76,107,000 Mb [hg19] on chromosome 6; ~1 probe per
5.9 Kb; Agilent Technologies).
We performed targeted resequencing of all genes within
the candidate region in subjects III-6 and III-10. Probes
recognizing coding exons between positions 20,402,398
and 98,664,560 bp on chromosome 6, as well as 2 Kb
upstream and downstream of the 50 UTR and 30 UTR of
all genes, were designed with eArray (Agilent). They repre-
sented 3,307 regions (1.3 Mb), 2,837 of which had non-
repeated sequences and were finally captured in the DNA
of subjects III-6 and III-10 of family SCA38-01-BS with a
custom target-enrichment method (SureSelect Agilent
array). The enriched samples were sequenced on the
Applied Biosystems SOLiD platform. Reads of 50 bp
(50,513,128 and 44,906,479 reads for affected individuals
III-10 and III-6, respectively) were aligned to hg19 with
Bioscope v.1.3 (Applied Biosystems) with default parame-
ters. For subjects III-6 and III-10, approximately 49.2%
and 47.8% of the sequences, respectively, matched the tar-
geted region, and 85.4% and 85.5% of the targeted regions,
respectively, were covered at least 303; also, the average
coverage was 1703 and 1473, respectively, and a total of
9,669 and 10,341 variants, respectively, were identified.
Sequences were then analyzed with the Gene Variant
Analyzer (v.1.2), an in-house tool developed at the IBiSA
Transcriptomics and Genomics facility of Marseille-
Luminy (France). Variants not shared by both the affected
individuals, homozygous variants, and variants reported as
validated polymorphisms in human variation resources
(dbSNP132, 1000 Genomes, NHLBI Exome Sequencing
Project Exome Variant Server [EVS], or HapMap) were
filtered out. Candidate genes were prioritized on the basis
of potentially damaging variants.9The AmerAmong 91 heterozygous protein-altering variants shared
by both subjects, we identified fivemissense variants with a
database frequency< 0.1%. Twowere excluded on the basis
of their nonconservation in mammals and considered
to be tolerated by SIFT and MutationTaster: c.821C>G
(p.Pro274Arg) (RefSeq accession numb NM_005865.3) in
protease, serine, 16 (thymus) (PRSS16 [MIM 607169]) and
c.821A>G (p.His274Arg) (RefSeqNM_152880.3) in protein
tyrosine kinase 7 (PTK7 [MIM601890]). Twoother variants,
c.5682A>T (p.Glu1894Asp) (RefSeqNM_015153.3) in PHD
finger protein 3 (PHF3 [MIM 607789]) and c.11901G>C
(p.Leu3967Phe) (RefSeq NM_015548.4) in dystonin (DST
[MIM 113810]), were not confirmed by Sanger sequencing.
The last variant, c.689G>T (p.Gly230Val) (RefSeq NM_
021814.4), was found in exon 7 of ELOVL5, which encodes
an enzyme involved in the elongation of polyunsaturated
fatty acids (PUFAs).10
Supporting ELOVL5 mutations as causative of SCA38, a
mutation in its paralog, ELOVL4 (MIM 605512), has been
recently described in a single family affected by an auto-
somal-dominant form of cerebellar ataxia and erythroker-
atodermia (SCA34 [MIM 133190]).11 Mutations in ELOVL4
can also cause autosomal-dominant Stargardt disease 3
(MIM 600110)12,13 and ichthyosis, spastic quadriplegia,
and mental retardation (MIM 614457).14
We screened ELOVL5 (conditions are reported in Table
S2) in 456 index European individuals with most likely
autosomal-dominant ataxia with an unknown genetic
cause; these individuals were collected by the SPATAX
network and other collaborators with approval from
local ethics committees. We identified one heterozygous
missense mutation (c.214C>G [p.Leu72Val] in exon 3) in
a family of French origin and the c.689G>T (p.Gly230Val)
mutation in two families of Italian origin (Figures 1A–1C).
Two further changes were unlikely to be mutations (Table
S3). We demonstrated segregation of the c.689G>T
(p.Gly230Val) mutation with the disease in a total of 20
available affected subjects from families SCA38-01-BS,
SCA38-02-CA, and SCA38-03-TO (Figure 1A). Both
c.214C>G and c.689G>T were absent in dbSNP137,
1000 Genomes, and the NHLBI EVS (13,006 chromo-
somes) and in 800 chromosomes from healthy controls.
The protein changes affect highly conserved amino acids
in vertebrates and are predicted to be damaging by bioin-
formatics tools (Figure 1D; Table S4).
Haplotype comparison among the three Italian families
carrying the c.689G>T (p.Gly230Val) substitution showed
that it was associated with the same SNP haplotype
covering 66.4 Kb (Table S5) (13% in the Italian TSI [Toscani
in Italia] population). Thehaplotype—extended to 25.8Mb
with short-tandem-repeat markers—suggested a common
ancestor in families SCA38-01-BS and SCA38-03-TO (Fig-
ures S1C and S2). For family SCA38-02-CA, sharing of the
SNP haplotype might suggest a more ancient progenitor
or two independent de novo c.689G>T mutations.
All affected individuals had common clinical features
(Table 1). Initial symptoms were truncal ataxia and gaitican Journal of Human Genetics 95, 209–217, August 7, 2014 211
Table 1. Clinics and Neuroradiology in SCA38-Affected Individuals
Family SCA38-01-BS
Family
SCA38-
02-CA
Family
SCA38-
04-FR
II-3 III-1 III-3 III-6 III-10 IV-1 IV-2 IV-8 II-2
Sex male female female female female female male female female
Age at examination
(years)
81 77 79 59 60 47 45 40 63a
Age at onset of gait
ataxia (years)
45 40 34 45 38 38 38 35 51
Disease duration (years) 36 37 35 14 22 9 7 14 12
Time from disease onset
to wheelchair use (years)
30 NA 25 NA NA NA NA  10
Initial symptom walking
difficulties
walking
difficulties
walking
difficulties
walking
difficulties
walking
difficulties
walking
difficulties
walking
difficulties
walking
difficulties,
nystagmus
walking
difficulties
Neurology
Gait ataxia þþþ þþþ þþþ þþ þþ þ þ þþ þþþ
Dysarthria þþ þ þ  þ   þ þþ
Slow saccades þþ þþ þþ þ þ    
Nystagmus þ þþþ þþþ þþþ þþþ þþ þþ þ 
Distal weakness        þ þ
Myoclonus         
Tremor  þ       
Peripheral neuropathy þþ NA þþ þ    þ þ
Extrapyramidal         
Sensory loss þþ  þ  þ    þ
Brain MRI
Vermian atrophy þþþ NA þþþ þþ þþ þ NA þ þþ
Brainstem atrophy  NA     NA  
Others Signs
Cognitive impairment         psychiatric
problems
Amino acid change p.Gly230Val p.Gly230Val p.Gly230Val p.Gly230Val p.Gly230Val p.Gly230Val p.Gly230Val p.Gly230Val p.Leu72Val
Abbreviations are as follows: , none; þ, mild; þþ, moderate; þþþ, severe; and NA, not available.
aDied at 65 years of age.disturbance with an onset at about 40 years (up to 51
years in family SCA38-04-FR). Gaze-evoked nystagmus
was always associated. Symptoms progressed very slowly.
During the disease course, affected individuals had been
able to walk until 50 years of age; later, they needed a
walking stick. Dysarthria, as well as limb ataxia, was
progressively evident. In two cases, diplopia was ob-
served. Mild to moderate axonal neuropathy was diag-
nosed in five subjects. Mild sensory complains were
reported in four affected individuals. Arterial hyperten-
sion and type 2 diabetes were present in one affected sub-
ject each. Cognitive disturbances were not reported, but
individual II-2 (with c.214C>G [p.Leu72Val]) had psychi-
atric problems.212 The American Journal of Human Genetics 95, 209–217, August 7Structural neuroimaging (MRI) revealed cerebellar atro-
phy without obvious brainstem involvement in the mod-
erate-severe stages (Figure 2A). In mid disease stages, MRI
was within the normal range, but brain FDG-PET scans
showed clear-cut cerebellar hypometabolism (Figure S3).
ELOVL5belongs to amultigenic family of genes encoding
elongases. These enzymes are located in the endoplasmic re-
ticulum(ER)andsynthesizevery-long-chain fattyacidswith
more than 16 carbons. Each elongase has its own substrate
specificity, but there is some functional overlap.16 ELOVL5
is involved in the synthesis of PUFAswithmore than 20 car-
bons of both the u3 and u6 series (double bond [C ¼ C] at
the third and sixth carbon atoms, respectively, from the
end of the chain),17,18 as shown by Elovl5-knockout mice,, 2014
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Figure 2. MRI Scans, ELOVL5 Expression, ELOVL5 Localization, and PUFA Serum Levels
(A) MRI scans of an affected individual (III-10 in family SCA38-01-BS). Coronal, midsagittal, and horizontal sections are reported.
Cerebellar atrophy with vermis involvement is shown; the cortex and brainstem are preserved.
(B) The normal expression pattern of ELOVL5 in five human tissues, lymphoblastoid cells, and four brain areas (mean5 SD). ELOVL5
showed prominent expression in brain and lung. Gene expression was measured by quantitative PCR with FAM-labeled Universal
ProbeLibrary LNA probes (Roche Diagnostics) (Table S6).
(C–F) Micrographs of sections of healthy human (C and E) and murine (D and F) cerebellar cortex immunostained with ELOVL5 anti-
body. Human cerebellar sections were obtained from paraffin-embedded tissues of postmortem brain derived from a healthy subject.
Sections were incubated with ELOVL5 polyclonal antibody (C15621, diluted 1:400, AssaybIoTech) and counterstained with hematox-
ylin. Higher magnifications of sections of human and mouse cerebellar cortex are shown in (E) and (F), respectively. Note the similar
labeling pattern of human and mouse Purkinje cells and the presence of numerous labeled cells in the white matter. Abbreviations
are as follows: ml, molecular layer; PCl, Purkinje cell layer; gl, granular layer; and wm, white matter. Scale bars represent 200 mm (C),
80 mm (D), 50 mm (E), and 20 mm (F).
(G) Fatty-acid analysis in serum isolated from whole blood of four affected individuals (III-10 in family SCA38-01-BS, IV-8 and IV-9 in
family SCA38-02-CA, and III-3 in family SCA38-03-TO). Fatty acids were analyzed in the serum from affected and control individuals
by liquid chromatography-tandem mass spectrometry.15 Reduced AA and DHA were measured in affected individuals (mean 5 SEM;
AA, *p < 0.05; DHA,*p < 0.05). Statistical analysis was performed with a one-tailed unpaired t test.
(H) Quantitative real-time PCR on the affected individuals’ cDNA showed an increase in ELOVL5 expression in comparison to the TBP
reference (mean5 SEM; ***p < 0.001, Mann Whitney test; **p < 0.01, two-tailed unpaired t test, Welch’s correction).
(I) ELOVL5 showed higher amounts in comparison to b-actin (ACTB) (mean5 SEM; ***p < 0.001, MannWhitney test; **p < 0.01, two-
tailed unpaired t test, Welch’s correction). Total proteins were extracted from lymphoblasts of five affected individuals (III-6 and III-10 in
family SCA38-01-BS and IV-8, IV-9, and IV-12 in family SCA38-02-CA) and five age- and origin-matched healthy controls. ELOVL5
amounts were normalized to ACTB. Different symbols indicate different affected individuals. The asterisk indicates an uncharacterized
immunoblot signal as demonstrated in Elovl5-knockout mice (see Figure S3A). Lanes 1 and 2 are affected individuals IV-8 and IV-9,
respectively, of family SCA38-02-CA; lanes 3 and 4 are two healthy controls.which have decreased synthesis of arachidonic acid (AA,
20:4, u6), eicosapentaenoic acid (EPA, 20:5, u3), and doco-
sahexaenoic acid (DHA, 22:6, u3).10
ELOVL5 mRNA showed ubiquitous expression in dif-
ferent human tissues and prominent expression in adult
brain and lung (Figure 2B). We explored the protein local-
ization pattern in the cerebellum of human and mouse
control samples. In Purkinje cells, the protein localized toThe Amerthe soma and the proximal portion of the dendritic tree
(Figures 2C–2F), strengthening the likelihood that disrup-
tion of this gene plays a role in the pathogenesis of SCA38.
To verify ELOVL5 activity, we quantified very-long-
chain fatty acids in the serum of four affected subjects
with the c.689G>T (p.Gly230Val) mutation. We detected
a significantly decreased level of two PUFAs directly syn-
thesized by ELOVL5: AA and DHA (Figure 2G).ican Journal of Human Genetics 95, 209–217, August 7, 2014 213
Lipid metabolism is strictly regulated by feedback loops
that control the synthesis of enzymes whenever the
amount of their products is altered. In Elovl5-knockout
mice, EPA and DHA reduction induces an increase in the
nuclear form of the transcription factor sterol regulatory
element binding protein 1c (SREBP-1c),10 which is known
to induce the expression of Elovl5 and several other
lipogenic genes involved in fatty-acid and triglyceride syn-
thesis. In lymphoblasts from affected individuals, ELOVL5
was significantly increased at both the mRNA level (2.05
0.2, mean 5 SEM, unpaired t test, p ¼ 0.0011; Figure 2H;
Table S6) and the protein level (2.85 5 0.4, mean 5
SEM, unpaired t test, p ¼ 0.0023; Figure 2I; Figure S4A).
Moreover, we demonstrated increased expression at the
mRNA level of ELOVL6 (MIM 611546), a typical SREBP-
1c target gene (2.5 5 0.1, mean 5 SEM, unpaired t test,
p ¼ 0.0012, data not shown).
This loop is responsible for an accumulation of lipids in
the Elovl5-knockout mouse liver, leading to hepatic steato-
sis.10 Neither this feature nor other metabolic anomalies
were evidenced in SCA38-affected individuals, suggesting
that the wild-type ELOVL5 allele has a compensatory resid-
ual function. However, given the specific expression of
ELOVL5 in Purkinje cells, a reduction in DHA and EPA
synthesis might have an effect on the cerebellum,
although Elovl5 ablation in mice does not display an overt
neurologic phenotype, but this deserves further careful
investigation.10
Lipid metabolism plays an important role in pre- and
postnatal development and normal functioning of the
CNS, given that this organ has the highest lipid content
after adipose tissue. Altered levels of lipid molecules,
such as fatty acids, are demonstrated in the neuronal sys-
tem of individuals affected by neurodegenerative diseases,
mental disorders, stroke, and trauma.
A variety of other neurological diseases, particularly he-
reditary spastic paraplegias19–23 and related diseases,24
also have altered lipid metabolism, which confirms the
importance of lipid homeostasis in brain membranes. In
particular, knocking down the biosynthesis of gangliosides
affects the composition of membranes on other lipid com-
ponents.25 Interestingly, activity of beta-glucosidase bile
acid glucocerebrosidase was found to be altered in a com-
plex phenotype characterized by spastic paraplegia with
cerebellar ataxia (SPG46 [MIM 614409]).21,26
On the other hand, missense changes in ELOVL5 might
lead to protein misfolding that alters the homeostasis
of subcellular compartments. To verify ELOVL5 mislocali-
zation, we prepared wild-type and mutant constructs
containing the full-length human ELOVL5 cDNA in
frame with a C-terminal HaloTag (pReceiver-M50, code
U1147, GeneCopoeia). Point mutations c.214C>G and
c.689G>T were introduced by PCR-induced mutagenesis
(primers are listed in Table S7). Subcellular localization
was studied by confocal microscopy in four different cell
types (COS-7, SK-N-BE2, NIH/3T3, and HeLa cells) (Fig-
ure 3; Figures S4B, S5, and S6).214 The American Journal of Human Genetics 95, 209–217, August 7Wild-type ELOVL5 mainly localized in the ER com-
partment, as expected by published data.27 In contrast,
p.Leu72Val and p.Gly230Val ELOVL5 had a less diffuse
ER signal but did show perinuclear and polarized subcellu-
lar localization (Figure 3A; Figures S5A and S6A), consistent
with an increase in the Golgi apparatus, as shown by the
Golgi marker GM-130, a peripheral cytoplasmic protein
tightly bound to the cis-Golgi membranes (Figure 3B; Fig-
ures S5B and S6B).28
The Golgi apparatus has a central role in the secretory
pathway. It is expected that any alteration of the Golgi pro-
teome would affect its homeostasis and consequently the
anterograde or retrograde protein trafficking through it.
TheGolgimight also serve as the last quality-control check-
point for correct protein conformation and activation of
the unfolded protein response (UPR).29,30 In particular,
the cis-Golgimight serve as a backupquality-control system
to retain and send back misfolded proteins to the ER.31
Misfolded ELOVL5 might escape ER control, accumulate
in the Golgi, and lead to chronic activation of the UPR,
as hypothesized for infantile hypophosphatasia (MIM
241500), which is caused by a p.Asn153Asp substitution
in alkaline phosphatase, tissue-nonspecific isozyme.32 The
UPR induces apoptosis by distinct overlapping mecha-
nisms, among which is the upregulation of the transcrip-
tion factor C/EBP-homologous protein (CHOP) via the
protein kinase RNA-like ER kinase.33 In p.Gly230Val-
transfected COS-7 cells, the amount of CHOP was
significantly increased, and it was slightly enhanced in
p.Leu72Val-tranfected cells (Figure S7).
Overall, our data show that the p.Gly230Val substitution
causes ELOVL5mislocalization andmight activate the UPR
(although this point requires further investigation). The
p.Leu72Val substitution might alter trafficking at the
Golgi, in terms of both receiving material from the ER
and recycling components back to the ER.34
On the basis of our screening, SCA38 is a rare hereditary
ataxia with an estimated incidence of <1% among Euro-
pean individuals affected by an autosomal-dominant
ataxia. This figure is in agreement with other SCAs due to
conventional mutations, where higher frequencies are
generally associated with founder effects.
Analogous with other SCAs caused by conventional
mutations, SCA38 has a pure cerebellar phenotype with a
progression slower than that of polyglutamine expan-
sions3 and joins an emerging group of neurological dis-
eases due to fatty-acids defects.Supplemental Data
Supplemental Data include seven figures and seven tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
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Figure 3. Subcellular Localization of Altered
ELOVL5 in COS7 Cells
COS-7 cells transfected with wild-type or mu-
tated (c.214C>G [p.Leu72Val] and c.689G>T
[p.Gly230Val]) ELOVL5 cDNAs. The day before
transfection, COS-7 (gray monkey kidney) cells
were seeded at 90% confluence in 500 ml
DMEM and 10% fetal bovine serum without
antibiotic. In vitro transfections were performed
with 500 ng of ScaI-digested linearized plasmid
and 1 ml Lipofectamine 2000 according to
the manufacturer’s (Life Technologies) instruc-
tions. After 24 hr, transfected cells were selected
for 7 days with the use of G418 (Invivo
Gen). Transfected COS-7 cells (5 3 104) were
seeded on fibronectin-coated coverslips (24-
well plates) and maintained with complete
medium (DMEM, GIBCO) at 37C. After 24 hr,
cells were incubated with HaloTag TMR
Direct Ligand at a final concentration of 1 mM
(Promega) and the indicated primary antibodies.
Samples were analyzed with an Olympus FV300
laser-scanning confocal microscope equipped
with a blue argon (488 nm) laser, a green
helium-neon (543 nm) laser, and FluoView
300 software (Olympus Biosystems). Cells were
imaged with a 603 oil-immersion objective
(1.4 NA). Images of optical sections (512 3 512
pixels) were digitally recorded and processed
with BioView software (Center for Bio-Image
Informatics).
(A) The ER is shown in green (rabbit anti-
calreticulin; C4606, 1:400, Sigma-Aldrich), and
ELOVL5 is shown in red (HaloTag TMR Direct
Ligand). The two proteins completely colocal-
ized in cells expressing wild-type ELOVL5, as
shown by the merge row. This pattern was
observed in 96% of cells (n ¼ 49) expressing
wild-type ELOVL5, 23% of cells (n ¼ 42) with
p.Leu72Val, and 17.5% of cells (n ¼ 40) with
p.Gly230Val (Fisher’s exact test performed be-
tween the wild-type and altered proteins, two-
sided, p < 0.0001). Scale bars represent 10 mm.
(B) The Golgi is shown in green (mouse anti-
GM130; 6108223, 1:400, BD Biosciences), and
ELOVL5 is shown in red. Both p.Leu72Val and
p.Gly230Val ELOVL5 were apparently reduced
in the ER andmislocalized to the Golgi compart-
ment, as shown by the merge row. This pattern
was observed in 80% of cells (n ¼ 40) expressing
wild-type ELOVL5, 83% of cells (n ¼ 47) with
p.Leu72Val, and 71% of cells (n ¼ 66) with
p.Gly230Val. Experiments were performed at
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